Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Stock Information for Ironwood Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
Millrose Properties Set to Join S&P SmallCap 600
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.